AtriCure (NASDAQ:ATRC) Price Target Raised to $55.00

AtriCure (NASDAQ:ATRC) had its price target boosted by stock analysts at BTIG Research from $45.00 to $55.00 in a research report issued to clients and investors on Monday, MarketBeat Ratings reports. The brokerage presently has a “buy” rating on the medical device company’s stock. BTIG Research’s price target would indicate a potential upside of 12.29% from the stock’s previous close.

A number of other brokerages have also issued reports on ATRC. Canaccord Genuity Group boosted their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Zacks Research upgraded shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 24th. Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. UBS Group dropped their target price on AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Finally, Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and a consensus price target of $48.62.

AtriCure Price Performance

AtriCure stock opened at $48.98 on Monday. AtriCure has a 12 month low of $25.36 and a 12 month high of $49.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The business has a 50 day simple moving average of $35.83 and a 200-day simple moving average of $31.81. The stock has a market capitalization of $2.49 billion, a PE ratio of 233.25 and a beta of 1.20.

AtriCure (NASDAQ:ATRC) last posted its quarterly earnings data on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The firm had revenue of $153.60 million for the quarter, compared to analyst estimates of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period last year, the firm posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts predict that AtriCure will post 0.2 earnings per share for the current year.

Insider Activity at AtriCure

In other news, Director Sven Wehrwein sold 25,000 shares of the stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares in the company, valued at $1,533,201.12. This represents a 38.16% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Karen Prange sold 3,564 shares of the firm’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $38.80, for a total transaction of $138,283.20. Following the completion of the sale, the director directly owned 22,809 shares in the company, valued at $884,989.20. This represents a 13.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 44,246 shares of company stock worth $1,691,895. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. purchased a new stake in AtriCure during the second quarter valued at about $37,000. Harbor Investment Advisory LLC purchased a new stake in AtriCure during the 2nd quarter worth $40,000. Allworth Financial LP acquired a new stake in AtriCure in the 2nd quarter valued at $43,000. Smartleaf Asset Management LLC increased its holdings in AtriCure by 59.8% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after purchasing an additional 429 shares in the last quarter. Finally, Fifth Third Bancorp purchased a new position in AtriCure in the first quarter valued at about $51,000. 99.11% of the stock is currently owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.